BioSpace

BioSpace
  • 0.0 (0)
  • Life Sciences
  • Updated weekly

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

  1. Rethinking hair loss treatment

    14 min ago

    Rethinking hair loss treatment

    In this episode of Denatured, you'll be hearing from Daniel Gil, CEO of Pelage Pharmaceuticals and Francisco Ramírez-Valle, senior vice president of immunology discovery at Eli Lilly. We dive into the long-overlooked hair loss space, exploring why true innovation has lagged, how a regenerative approach aims to reactivate dormant follicles and what early proof-of-concept means for patients. Host Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Daniel Gil, CEO, Pelage Pharmaceuticals Francisco Ramírez-Valle, Senior Vice President, Immunology Discovery, Eli Lilly Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    22 min
  2. ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck

    13 hr ago

    ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck

    At the American Society of Clinical Oncology (ASCO) annual meeting in Chicago this past weekend, packed plenary sessions from Revolution Medicines and Summit Therapeutics’ Chinese partner Akeso stole the show. For RevMed, analysts anticipate a potential approval in pancreatic cancer as early as this year, while Summit still has a tough road ahead showing that the survival benefit seen in Akeso’s clinical trial in China will hold up in a global population. Immuneering, BMS/BioNTech, Merck, Pfizer and many more also scored oncology wins at the annual meeting, as did Moderna, with “encouraging” 5-year survival for its mRNA-based personalized melanoma vaccine. Outside of ASCO, the past week saw Pfizer strike an unusual pact with China’s Innovent Biologics as it seeks to bolster its oncology pipeline. Reminiscent of another recent deal from BMS and Hengrui Pharma, it could signal a more collaborative approach to working with Chinese companies. We’ll also cover the latest deals from Eli Lilly, which continues to rack up partners with its GLP-1 windfall. Finally, learn about how BrainStorm is planning another FDA bid for its experimental ALS therapy NurOwn with former regulator Peter Pitts now on the board, and check out a preview of the 2026 American Diabetes Association, or ADA, which kicks off this weekend in New Orleans.

    27 min
  3. France’s biotech ecosystem: science, capital and scale

    6 days ago

    France’s biotech ecosystem: science, capital and scale

    In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you'll be hearing from Ksenija Pavletic, partner and chief commercial officer at Jeito Capital and Thierry Laugel, managing partner at Kurma Partners. We dive into France’s biotech ecosystem and what still needs to happen for more early innovation to translate into investable, scalable biotech. Host ⁠Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Ksenija Pavletic, Partner and Chief Commercial Officer, Jeito Capital Thierry Laugel, Managing Partner, Kurma Partners Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    21 min
  4. Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds

    27 May

    Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds

    Eli Lilly has been as acquisitive as ever, striking five new deals in the past week alone. On Tuesday, the company dove into the deep end of vaccine development with three separate buys in the space. Outside of vaccines, Lilly scooped up preclinical biotech Engage Bio for $202 million and teamed up with AI company Collaborative Drug Discovery for its life sciences data management solutions. These deals and Lilly’s skyrocketing revenue pushed the Indianapolis-based company to the top of IDEA Pharma’s list of best inventors and innovators. Lilly also continues to make headlines for its impressive data readouts, especially in the weight-loss space that it now reigns supreme. Last week, Lilly announced that next-gen asset retatrutide led to weight loss of 70 pounds, or 28.3% at 80 weeks, setting a new benchmark for the space. Moderna also made news this week with a surprising uptick in its share price that analysts are attributing to the so-called “fear trade” that is rising amid reports of a cluster of cases of hantavirus. Moderna also announced that its mRNA flu shot—initially turned away from the FDA but later accepted for review—will be discussed at an advisory committee on June 18. The annual conference of the American Society of Clinical Oncology starts on Friday in Chicago, where all eyes will be on Revolution Medicines’ investigational pancreatic cancer pill and Akeso’s Phase 3 trial HARMONi-6 for its Summit Therapeutics-partnered PD-1/VEGF bispecific ivonescimab. Finally, sign up for BioPharma Executive to receive this week’s special edition breaking down executive compensation packages across the biggest pharmas.

    25 min
  5. Inside Germany’s biotech capital infrastructure and innovation engine

    21 May

    Inside Germany’s biotech capital infrastructure and innovation engine

    In this episode of Denatured, as part of our series of the European life science investment ecosystem, you'll be hearing from Regina Hodits, managing director at Angelini Ventures and Sofia Ioannidou, VC partner at Andera Life Sciences. They examine Germany’s biotech and life sciences landscape, focusing on the scientific, infrastructure and policy shifts required to enable European companies to scale globally while remaining anchored in Europe. Host ⁠Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Regina Hodits, Managing Director, Angelini Ventures Sofia Ioannidou, VC Partner, Andera Life Sciences Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    23 min
  6. FDA’s absent leaders, the millions pharma CEOs make, and pancreatic cancer’s momentum

    20 May

    FDA’s absent leaders, the millions pharma CEOs make, and pancreatic cancer’s momentum

    FDA Commissioner Marty Makary officially resigned last week following reports of his ouster. Then, the acting directors for the agency’s two main review units also left their posts, as did the FDA chief of staff and chief AI officer. Domino effect aside, the reaction from the industry has been mostly positive, given Makary’s tumultuous reign. But he might be hard to replace. If it were up to the biotech industry, former longtime oncology regulator and short-lived CDER director Richard Pazdur would take the role. For now, FDA Deputy Commissioner for Food Kyle Diamantas is in charge. Eli Lilly’s David Ricks was the highest paid pharma CEO last year, but J&J’s Joaquín Duato made the most relative to rank-and-file employees, with a median pay ratio of 358 to one. He was on the top of BioSpace’s list last year, too, with a ratio of 293 to 1. Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. This week, Truist Securities went so far as to nominate RevMed as “the next oncology titan,” a title currently held by Merck and its blockbuster cancer drug Keytruda. Safety continues to challenge the gene therapy space, especially in Duchenne muscular dystrophy. Late last week, REGENXBIO announced mixed results from a Phase 3 program—the gene therapy did lead to functional improvements, but two serious adverse events caused the stock to drop 37%. Finally, Amgen’s rare disease drug Tavneos continues to face scrutiny. Last month, the FDA alleged that doctored data were filed to support Tavneos’ initial approval. Now, it’s been linked to 20 deaths in Japan.

    27 min
  7. From MSCs to iPSCs: building the cell therapy future

    14 May

    From MSCs to iPSCs: building the cell therapy future

    In this episode of Denatured, you'll be hearing from Miguel Forte, president of the International Society for Cell and Gene Therapy (ISCT), and John Ellis, co-founder & CEO of Trenchant Bios, speaking live from the ISCT annual meeting. We dive into mesenchymal stem cells and induced pluripotent stem cells, exploring the science behind them, the manufacturing challenges, and the potential for scalable, engineered next-generation therapies. Host Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Jon Ellis, Co-founder & CEO, Trenchant Bio Miguel Forte, President, International Society for Cell & Gene Therapy Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    20 min
  8. Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay

    13 May

    Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay

    Moments after recording this episode of The Weekly, FDA Commissioner Marty Makary announced his resignation. Reports first circulated last Friday that President Donald Trump had signed off on his ouster. The president initially denied this account, originally from The Wall Street Journal, on Saturday morning, but appears to have now confirmed the plan.   This confusion underscores a key theme in Robert F. Kennedy Jr.’s health department: lack of transparency and clear communication. Makary’s exit also highlights the high level of senior leadership turnover across the Department of Health and Human Services. With Makary is on his way out, the FDA will reportedly be helmed by an acting commissioner, Kyle Diamantas. This would also be fitting for an agency whose two key review divisions—the Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER)—are currently led by temporary directors.   Meanwhile, one of Makary’s key initiatives, the Commissioner’s National Priority Review (CNPV) program, hit a snag last week as Sanofi has reportedly requested that the FDA remove its diabetes prevention drug Tzield from the scheme. This comes after acting CDER director Tracy Beth Høeg apparently intervened in the drug’s review.   And in the business realm, BioSpace kicks off our annual compensation report. Who made the most money in 2025? Was it Eli Lilly’s David Ricks or Johnson & Johnson’s Joaquin Duato? Read BioPharm Executive to find out. Not subscribed? Sign up here for all of BioSpace’s insightful newsletters.

    16 min
See All (236)

About

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

Information

  • Creator
    BioSpace
  • Years Active
    2023 - 2026
  • Episodes
    236
  • Rating
    Clean
  • Copyright
    © 2026 BioSpace
  • Show Website
    BioSpace

You Might Also Like